---
title: "Kingmed Diagnostics: Expected net profit loss of RMB 65 million to RMB 95 million in the first half of 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/248383201.md"
description: "Kingmed Diagnostics announced that it expects to achieve a net profit attributable to shareholders of the listed company of -65 million yuan to -95 million yuan for the first half of 2025, a year-on-year turnaround from profit to loss. It is expected that the net profit attributable to shareholders of the listed company, after deducting non-recurring gains and losses, will be -78 million yuan to -110 million yuan for the first half of 2025"
datetime: "2025-07-14T09:23:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/248383201.md)
  - [en](https://longbridge.com/en/news/248383201.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/248383201.md)
---

# Kingmed Diagnostics: Expected net profit loss of RMB 65 million to RMB 95 million in the first half of 2025

Kingmed Diagnostics announced that it expects to achieve a net profit attributable to shareholders of the listed company of -65 million to -95 million yuan for the first half of 2025, a year-on-year turnaround from profit to loss. It is expected that the net profit attributable to shareholders of the listed company, after deducting non-recurring gains and losses, will be -78 million to -110 million yuan for the first half of 2025

### Related Stocks

- [603882.CN](https://longbridge.com/en/quote/603882.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [BYD is struggling to meet demand for new fast-charging EVs as orders reach 100K, 60K](https://longbridge.com/en/news/287109883.md)
- [11:23 ETTOUS les JOURS BRINGS OFFICIAL BTS THE CITY ARIRANG POP-UP EXPERIENCE TO LAS VEGAS BAKERY CAFÉS](https://longbridge.com/en/news/286793282.md)
- [Europe-China spacecraft launches to study Earth's 'invisible armour'](https://longbridge.com/en/news/286881963.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)